{"id":391396,"date":"2015-05-26T00:00:00","date_gmt":"2015-05-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1115-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-physician\/"},"modified":"2026-03-31T09:03:49","modified_gmt":"2026-03-31T09:03:49","slug":"pforus1115-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-physician","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1115-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-physician\/","title":{"rendered":"Non-Hodgkin\u2019s Lymphoma and Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma | Physician &#038; Payer Forum | US | 2015"},"content":{"rendered":"<p><em>How Will U.S. Payer and Prescriber Attitudes Shape This Competitive Market? <\/em><\/p>\n<p>The treatment of non-Hodgkin\u2019s lymphoma (NHL) and chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) in the United States is centered on the use of Roche\/Genentech\u2019s Rituxan. This monoclonal antibody (MAb) has demonstrated clear improvements in clinical practice, and is still enjoying significant commercial success nearly two decades after its launch. Recent approvals of small-molecule inhibitors Imbruvica and Zydelig are becoming increasingly entrenched in the NHL and CLL\/SLL treatment algorithms, while MAbs developed to challenge Rituxan\u2014Novartis\u2019s Arzerra and Roche\/Genentech\u2019s Gazyva\u2014face considerable competition from Rituxan\u2019s dominance in the marketplace.<\/p>\n","protected":false},"template":"","class_list":["post-391396","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-oncology","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391396\/revisions"}],"predecessor-version":[{"id":576961,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391396\/revisions\/576961"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}